Bispecific antibodies have transformed treatment by simultaneously targeting two molecules, delivering significant clini...
Although each rare disease affects only a small number of people, collectively they represent one of the world's largest...
Ember LifeSciences, Inc. has entered into a capital and business alliance with Alfresa Corporation, a subsidiary of Alfr...
AbbVie has announced the availability of ELAHERE® (mirvetuximab soravtansine) in Singapore for the treatment of plat...
Japan-based Ono Pharmaceutical and US-based Phylo, Inc. have announced a collaboration that brings Biomni Lab, Phylo's a...
DKSH Business Unit Healthcare, a strategic healthcare solutions partner and leading provider of Market Expansion Service...
Asia's biopharmaceutical manufacturing sector is entering a new phase of growth, driven by expanding biologics pipelines...
Nippon Kayaku and Celltrion Healthcare Japan K.K. have entered into a Memorandum of Understanding (MoU) on Compreh...
Takeda China has announced that the National Medical Products Administration (NMPA) has approved the use of ORZEYFUL (ov...
It is estimated that by 2040 China-originated treatments will represent 35% of US FDA approvals. When marketing treatmen...
GCCL, a South Korea-based leading provider of clinical trial sample analysis, and China & US based GemPharmatech, a ...
Gerresheimer, an innovative system and solution provider and global partner to the pharma, biotech, and cosmetic industr...
Devonian Health Group has received Health Canada authorisation to initiate a Phase II/III paediatric clinical trial of P...
The Ministry of Health and Welfare (MoHW), South Korea, and Novartis have signed a Memorandum of Understanding (MoU) und...
ING has examined the shifting global pharmaceutical landscape in a podcast discussion focused on China’s biotech b...
Monash University has signed a Memorandum of Understanding (MoU) with Australia’s Therapeutic Goods Administration...
JCR Pharmaceuticals Co., a global specialty biopharmaceutical company dedicated to developing therapies for rare and gen...
Halozyme Therapeutics has entered a global collaboration and licence agreement with Incyte to evaluate additional subcut...
Fangzhou Inc. has announced the launch of Kyinsu®, the world's first once-weekly basal insulin/GLP-1 RA combination ...
Galderma has announced the launch of Alastin – its premium regenerative skincare brand – across the JPAC reg...
Merck, a leading science and technology company, has opened a new €25 million BioReliance® testing facility at ...
Menarini Asia-Pacific has announced an exclusive partnership with Pharmacosmos A/S to register, commercialise and distri...
AstraZeneca has entered into an exclusive license agreement with China-based Dizal Pharmaceutical for Zegfrovy ...
India's Sai Parenterals has announced that its Australian subsidiary, Noumed Pharmaceuticals, has successfully renewed i...
Drug development is approaching a significant inflection point. Advances in induced pluripotent stem cells (iPSCs), orga...
